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Abstract 
Background: Emergency department staff play a crucial role in the triage of stroke patients and therefore the capac‑
ity to deliver time‑dependent treatments such as tissue Plasminogen Activator. This study aimed to identify among 
emergency physicians, (1) rates of agreement with evidence supporting tissue Plasminogen Activator use in acute 
stroke care; and (2) individual and hospital factors associated with high agreement with evidence supporting tissue 
Plasminogen Activator use.
Methods: Australian fellows and trainees of the Australasian College for Emergency Medicine were invited to 
complete an online cross‑sectional survey assessing perceptions of tissue Plasminogen Activator use in acute stroke. 
Demographic and hospital characteristics were also collected.
Results: 429 Australasian College for Emergency Medicine members responded (13% response rate). Almost half 
(47.2%) did not agree with any statements regarding the benefits of tissue Plasminogen Activator use for acute stroke. 
Perceived routine administration of tissue Plasminogen Activator by the head of respondents’ emergency department 
was significantly associated with high agreement with the evidence supporting tissue Plasminogen Activator use in 
acute stroke.
Conclusions: Agreement with evidence supporting tissue Plasminogen Activator use in acute stroke is not high 
among responding Australian emergency physicians. In order for tissue Plasminogen Activator treatment to become 
widely accepted and adopted in emergency settings, beliefs and attitudes towards treatment need to be in accord‑
ance with clinical practice guidelines.
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Background
Stroke and tissue Plasminogen Activator (tPA)
Globally, stroke is the third most common cause of dis-
ability-adjusted life years (DALYs) [1]. Thrombolytic 
therapy using intravenous tPA is both an effective [2] 
and cost-effective [3] treatment in eligible acute ischemic 
stroke patients, significantly improving the chance of 
a good recovery when used in accordance with strict 
protocols [4]. However, tPA carries risk of haemorrhage 
[4] and can only be administered within 4.5  h of stroke 
onset [5], which provides challenges to its widespread 
use. Currently 53% of Australian hospitals report offering 
[6], and 7% of patients receive, tPA treatment [7]. Rates 
of use are lower in other countries; 5% of stroke patients 
receive tPA in the United Kingdom (UK) [8] and 2.4% of 
ischemic stroke patients receive tPA in the United States 
(US) [9].
Physicians’ attitudes towards tPA
Emergency department (ED) staff play a crucial role in 
the triage and in-hospital care of stroke patients. Timely 
Open Access
*Correspondence:  Alice.Grady@newcastle.edu.au 
1 Priority Research Centre for Health Behaviour, Hunter Medical Research 
Institute (HMRI), University of Newcastle, Callaghan, NSW 2308, Australia
Full list of author information is available at the end of the article
Page 2 of 8Grady et al. BMC Res Notes  (2015) 8:267 
assessment and referral in line with clinical guidelines is 
particularly important for stroke patients eligible for tPA 
treatment. Emergency physicians may be responsible for 
the treatment of stroke patients in hospitals without ded-
icated specialists.
Risks associated with tPA in acute stroke may con-
tribute to physician uncertainty in administering treat-
ment [4]. A 2005 survey of US emergency physicians 
indicated 40% were unlikely to administer tPA for acute 
stroke in an ideal setting [10]. Attitudes may be shift-
ing with a 2010 survey showing that 17% of emergency 
physicians were uncertain or unlikely to administer tPA 
in an ideal setting [11]. However, the latter survey was 
limited to emergency physicians from community hos-
pitals participating in a cluster randomised controlled 
trial [11]. A 2004 New Zealand (NZ) survey indicated 
73% of physicians rarely or never administer tPA treat-
ment [12]. This sample included a range of health-care 
providers, limiting the generalisability of findings to the 
emergency context.
A discrepancy between the optimum hospital environ-
ment outlined in clinical guidelines and the actual set-
tings in which tPA treatment is administered may also 
contribute to implementation challenges [6, 13]. Further-
more, in 2013, Australia’s National Stroke Foundation 
(NSF) reported 24% of hospitals without a stroke care 
unit (SCU) provide thrombolysis [6].
Emergency physicians’ perceptions of the evidence 
in support of tPA use in stroke have not been exam-
ined recently. Perceptions may have altered as a conse-
quence of public media campaigns [F.A.S.T (Face, Arm, 
Speech, Time) campaigns launched by NSF, American 
Heart Association (AHA) and American Stroke Asso-
ciation (ASA), and the UK’s Stroke Association], pub-
licised debate regarding potential benefits and risks of 
tPA treatment [14], and release of clinical guidelines 
with an increased time-frame for treatment [5, 15]. As 
such, an examination of whether attitudes of emergency 
health-care providers are supportive of tPA use in acute 
stroke, or whether they might be one of the factors lim-
iting tPA rates is required. The study successfully identi-
fied, among a sample of emergency physicians, (1) rates 
of agreement with evidence supporting tPA use in acute 
stroke care; and (2) individual and hospital factors asso-




An online cross-sectional survey of emergency physi-
cians in Australia was conducted July–August 2012. 
The University of Newcastle’s Human Research Ethics 
Committee and the Australasian College for Emergency 
Medicine (ACEM) Scientific Committee approved the 
study.
Participants
Australian trainees and fellows registered with ACEM 
were invited to participate. All emergency physician 
trainees and fellows within Australia are registered with 
ACEM, providing access to a representative sample of 
this specialty group. Fellows of ACEM have completed a 
minimum of 7 years post-graduate medical training, and 
participate in ongoing professional training to maintain 
this title.
Procedure
Potential participants were sent an email from ACEM 
containing an information statement and link to the sur-
vey. A reminder email was sent two weeks following ini-
tial correspondence. Completion of the survey was taken 
as implied consent.
Measures
Responders completed an online survey administered via 
Survey Monkey (see Additional file  1). Measures were 
developed based on recommended hospital facilities and 
evidence supporting tPA use according to NSF’s Clini-
cal Guidelines for Stroke Management [5]. Items were 
reviewed by two stroke specialists and two emergency 
physicians at a tertiary hospital to ensure they reflected 
findings from published literature. The survey was then 
pilot tested with five health behaviour researchers who 
reviewed the items to ensure comprehension. Items 
included:
Physician characteristics
Age; gender; role within the hospital; number of years 
worked in emergency care; and role in stroke care. De-
identified data on all fellows and trainees (gender and 
location) was obtained from ACEM to assess response 
bias.
Hospital characteristics
State; whether arrangements for pre-hospital notification 
from ambulance are in place; number of ischemic stroke 
patients presenting to ED per fortnight; an estimate of 
the proportion of stroke patients referred to an SCU or 
neurology department; presence of an SCU; presence of 
an intensive care unit (ICU); whether advanced imag-
ing facilities are available; whether the hospital provides 
tPA treatment; an estimate of the proportion of ischemic 
stroke patients receiving tPA treatment; an estimate of 
the proportion of emergency physicians giving tPA treat-
ment; and whether the head of ED routinely provides tPA 
treatment.
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Perception of tPA use in acute stroke
Participants were presented with six items reflecting 
published literature limited to the benefits of tPA use in 
acute stroke, and two items about their concerns using 
tPA treatment. Participants rated how much they agreed 
or disagreed with each item on a five point likert scale 
(strongly disagree [1] to strongly agree [5]). Participants 
were also asked ‘What would influence your views on the 
use of tPA in acute stroke?’ Response options included 
‘Guidance from a professional colleague’, ‘Guidance from 
an expert in the use of tPA for acute stroke’, ‘Additional 
clinical trials of tPA’, ‘Research conducted by ED staff’, 
and ‘Other’.
Data analysis
Descriptive statistics were calculated to describe the 
demographic and workplace characteristics of respond-
ers, and the survey responses. Characteristics of respond-
ers and grouped de-identified data on non-responders 
were compared using χ2 tests.
Each respondent received an accumulated score of 0–6 
based on their level of agreement with items. For each 
item the responses ‘strongly agree’ or ‘agree’ were given 
a score of 1 and all remaining responses a score of 0. 
“High agreement” was defined as an accumulated score 
of ≥4; “Low agreement” was a score of 1–3; and “No 
agreement” was a score of 0. The association between 
all physician and hospital characteristics on the level of 
agreement (“High agreement” vs “Low/No agreement”) 
with evidence for tPA use in acute stroke was evaluated 
separately using logistic regression. All variables identi-
fied as significant at a p-value of 0.2 or less were included 
in a stepwise logistic regression analysis. For the final 
multiple logistic regression, variables that met a signifi-
cance level of p < 0.05 were included in the model. Miss-
ing data were excluded.
Results
The study had 55 and 52% power at the 5% significance 
level to detect a 0.55/0.45 difference in proportions of 
respondents who agree/disagree with each item.
Response rate and physician characteristics
Of the 3,280 ACEM members invited to participate, 429 
responded (response rate = 13%). Results of chi-square 
analyses indicated males [Χ2 (1, n  =  3,278)  =  6.54, 
p = 0.01], and respondents working in Victoria [Χ2 (7, 
n = 3,280) = 33.10, p < 0.01] were more likely to par-
ticipate. Table  1 shows characteristics of responders 
and non-responders. Of those responsible for deciding 
which patients receive tPA, the median proportion of 
eligible patients perceived to be treated with tPA was 
15%.
Hospital characteristics
Table  2 outlines participants’ self-reported hospital 
characteristics. The average number of ischaemic stroke 
patients seen by the ED every fortnight was 14.1 (SD 
12.9). The median proportion of patients referred to a 
neurology department or SCU from emergency was per-
ceived to be 85%. Of the hospitals that provide tPA treat-
ment to eligible stroke patients, the median proportion of 
patients perceived to be treated with tPA by emergency 
physicians was 10%.
Physician agreement with evidence for tPA
Physician agreement with statements for tPA use is pro-
vided in Table  3. There were no significant differences 
Table 1 Demographics and  characteristics of  responders 
(n = 370) and non-responders (n = 2910)
Number of observations varies across characteristics due to missing data, multi-
response items, and item applicability.




Characteristic Mean (SD) Mean (SD)
Age 41.1 (8.2) NA
n (%) n (%)
Male 256 (69.2) 1814 (62.4)
Years worked in emergency 
care
NA
 ≤5 years 59 (15.9)
 5–10 years 92 (24.9)
 11–15 years 90 (24.3)
 ≥16 years 129 (34.9)
Role within the hospital* NA
 Emergency physician 229 (63.8)
 Emergency physician trainee 122 (34.0)
 Other 8 (2.2)
Location*
 New South Wales (NSW) 95 (26.5) 809 (27.7)
 Victoria (VIC) 108 (30.1) 715 (24.5)
 Queensland (QLD) 72 (20.1) 715 (24.5)
 South Australia (SA) 20 (5.6) 212 (7.3)
 Western Australia (WA) 27 (7.5) 331 (11.3)
 Northern Territory (NT) 10 (2.8) 34 (1.2)
 Australian Capital Territory 
(ACT)
8 (2.2) 44 (1.5)
 Tasmania (TAS) 19 (5.3) 61 (2.1)
Responsible for determining  
care provided to stroke 
patients*
293 (81.6) NA
Decide which patients receive 
tPA†
116 (41.7) NA
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in rates of agreement between those who reported their 
hospital did or did not provide tPA. 19.5% of respond-
ents had a high level of agreement with these statements, 
36.2% had a low level, and 47.2% agreed with none of the 
statements (Figure 1).
23.7% of respondents agreed they “have no concerns 
surrounding the legal implications of tPA use”, and 8.9% 
agreed they “have no concerns surrounding patient 
complications of tPA use”. When asked “What would 
influence your views on the use of tPA in acute stroke?” 
83.8% of participants indicated additional trials of tPA, 
60.3% reported research conducted by ED staff, 47.6% 
said guidance from an expert in the use of tPA for acute 
stroke, and 43.8% indicated guidance from a professional 
colleague would change their views.
Factors associated with agreement with evidence for tPA
No physician factors were significantly associated with a 
high level of agreement with statements supporting tPA 
use in stroke (Table 4). The perceived routine use of tPA 
by the head of ED was significantly associated with a high 
level of agreement with the evidence supporting tPA use 
(OR 3.87, 95% CI 1.49–10.04, p = 0.01) (Table 5).
Discussion
Even when allowing for the low response rate, study find-
ings suggest a sizeable minority of Australian emergency 
physician fellows and trainees do not agree with state-
ments supporting use of tPA in the treatment of acute 
stroke. Consideration of the participating physician and 
workplace characteristics may suggest that physicians 
from tertiary hospitals may be over-represented here, 
therefore, it is likely the majority of results apply to this 
sub-group.
Physician agreement with evidence for tPA
As emergency physicians are often the first contact for 
the in-hospital care of stroke patients, their attitudes 
towards tPA are a critical factor in the use and non-use 
of this treatment. Emergency physicians help shape treat-
ment protocols and as such, their perceptions influence 
the attitudes of others [16]. Given the utility of tPA in sig-
nificantly reducing disability associated with stroke [5], 
it is interesting that less than half (39.6%) of respondents 
agreed that appropriate use of tPA will improve the odds 
of independent survival for stroke patients.
Only a small proportion of participants agreed the 
evidence underpinning tPA use is strong when adminis-
tered within 4.5 h of stroke onset (16.8%), and that the 
Table 2 Hospital characteristics of responders (n = 359)





Arrangements are in place to receive pre‑hospital  
notification of stroke patients from the ambulance service
238 (66.3)
The hospital has a dedicated stroke care unit* 266 (74.3)
The hospital has an intensive care unit* 338 (94.4)
The hospital has advanced imaging facilities (perfusion CT 
and MRI)*
300 (83.8)
The hospital provides tPA treatment to eligible ischemic 
stroke patients*
278 (77.7)
The proportion of the emergency physicians at the hospital who rou‑
tinely administer tPA treatment for eligible ischemic stroke patients†
 None 184 (66.2)
 Less than half 33 (11.9)
 About half 8 (2.9)
 Most 36 (12.9)
 All 17 (6.1)
The head of the ED routinely administers tPA treatment for eligible 
ischemic stroke patients†
 Yes 32 (11.5)
 No 173 (62.2)
 I do not know 73 (26.3)
Table 3 Physician agreement with the evidence for tPA use in acute stroke care (n = 429)








Increasing appropriate use of tPA will:
 Save lives 185 (43.1) 155 (36.1) 89 (20.7)
 Not result in unnecessary adverse events 267 (62.3) 102 (23.8) 60 (14.0)
 Improve the odds of independent survival for stroke patients 109 (25.4) 150 (35.0) 170 (39.6)
The evidence underpinning tPA use:*
 Is strong when administered within 4.5 h of stroke onset 226 (54.4) 119 (28.7) 70 (16.8)
 Indicates that the benefits outweigh the risks if the treatment  
protocol is followed
134 (32.3) 107 (25.8) 173 (42.0)
 Is strong enough to warrant the use of this treatment 141 (34.0) 119 (28.7) 155 (37.4)
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evidence is strong enough to warrant use (37.4%). This is 
despite approval from the Australian Therapeutic Goods 
Administration for tPA use, and recommendations in 
the current Australian clinical practice guidelines [5]. 
Use of tPA is also approved up to 4.5 h post-stroke onset 
in the UK by the Medicines and Healthcare Products 
Regulatory Agency, and recommended up to 4.5  h by 
AHA and ASA [15]. These results may be indicative of 
the influence of authoritative emergency-specific bodies 
that openly do not support the use of tPA by emergency 
physicians.
Previous studies have identified limited acceptance of 
the evidence for tPA use in acute stroke [17]. Scott’s study 
of emergency physicians in the US found 49% agreed the 
science regarding the use of tPA in stroke is convincing 
[11]. Additionally, Wang reported 72% of responders 
recognised tPA is the preferred treatment for acute 
stroke, and 59% were aware of the limited time-window 
for administration [16]. While Wang’s outcomes may 
be biased due to the sampling procedure employed, and 
the inclusion of residents within family practice, inter-
nal medicine and neurology [16], these results highlight 
a lack of awareness regarding clinical practice guidelines 
for tPA use in acute stroke care.
Almost half of the respondents in our survey did not 
agree with any statements supporting tPA use in acute 
stroke, with only 20% of the respondents having “High 
agreement” with the literature. In order for tPA treat-
ment to become widely accepted and adopted in emer-
gency settings that have the necessary facilities, beliefs 
and attitudes towards treatment need to be in accordance 
with best-practice recommendations.
Reasons behind physician views of tPA
Research appears to be the key feature influencing atti-
tudes of tPA. A high proportion of respondents reported 
‘additional clinical trials of tPA’ (83.8%), and ‘research 
conducted by emergency department staff’ (60.3%) 
would influence their views. Indeed, there have been calls 
for additional clinical trials of tPA treatment to be con-
ducted [18], leading to re-analysis of the National Insti-
tute of Neurological Disorders and Stroke trial data [19], 
and the spread of uncertainty towards use of this therapy 
[20]. However, given the existing evidence-practice gap, 
serious consideration about whether additional trials of 
tPA will actually shift attitudes and practice surrounding 
the use of tPA, is crucial in determining the next steps 
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Figure 1 Emergency physicians’ level of agreement with evidence 
for tPA use (n = 415).
Table 4 Individual factors associated with high agreement with the evidence for tPA use in acute stroke care
Factors Crude odds ratio (95% CI) Adjusted odds ratio (95% CI) Adjusted p-value
Age 1.01 (0.98, 1.04) 1.06 (0.99, 1.13) 0.09
Gender
 Male 1.21 (0.69, 2.12) 0.96 (0.48, 1.92) 0.91
 Female
Role
 Other vs Emergency physician trainee 0.50 (0.06, 4.27) 0.60 (0.06, 6.02) 0.91
 Emergency physician vs Emergency physician trainee 0.91 (0.53, 1.55) 0.92 (0.32, 2.65)
Years worked in emergency care
 5 years or less vs 16 years or more 1.18 (0.55, 2.50) 2.37 (0.42, 13.31) 0.38
 6–10 years vs 16 years or more 0.94 (0.48, 1.87) 1.92 (0.47, 7.85)
 11–15 years vs 16 years or more 1.27 (0.66, 2.44) 2.30 (0.90, 5.92)
Does your role at the hospital include responsibility for determining the care that is provided to stroke patients?
 Yes 1.23 (0.62, 2.44) 0.92 (0.41, 2.07) 0.84
 No
Does your role at the hospital include deciding which patients receive tPA?
 Yes 1.60 (0.90, 2.85) 1.64 (0.89, 3.04) 0.11
 No
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Scott’s trial targeting hospital staff failed to produce a 
significant increase in use of tPA for stroke, the authors 
recognise that additional strategies to increase treatment 
are required [21].
Factors associated with agreement with evidence for tPA
Respondents were nearly four times more likely to have 
high agreement with the evidence supporting tPA use in 
acute stroke if they perceived their head of ED admin-
isters tPA treatment to eligible patients. This result is 
supported by the 43.8% of respondents who indicated 
guidance from a professional colleague would influence 
their views on the use of tPA. While no other studies have 
examined this relationship, one study found the presence 
of “uncompromising, individual clinical leadership” in 
a hospital setting was significantly associated with the 
likelihood of receiving tPA [22]. Results are indicative of 
the power of social influence and modelling in chang-
ing health providers’ attitudes and behaviour [23]. Social 
influences play an important role in the implementation 
of new behaviours, and by targeting provider knowledge, 
attitudes and social norms, opinion leaders can aid adop-
tion of new practices [24]. Demonstrating or modelling 
new skills, can build both skill and confidence to perform 
Table 5 Workplace factors associated with high agreement with the evidence for tPA use in acute stroke care
4th and 11th factors could not be included in the adjusted logistic regression model due to zero counts in some categories.
Factors Crude odds ratio (95% CI) Adjusted odds ratio (95% CI) Adjusted p-value
How many ischaemic stroke patients are seen by the emergency 
department every fortnight
1.00 (0.98, 1.02) 0.99 (0.97, 1.02) 0.63
The proportion that are referred to a stroke care unit or neurology 
department
1.00 (0.99, 1.00) 0.99 (0.98, 1.00) 0.28
The proportion of ischaemic stroke patients who are currently treated 
with thrombolysis at the hospital
1.00 (0.99, 1.02) 1.01 (0.99, 1.03) 0.32
Does the hospital provide tPA treatment to eligible ischaemic stroke patients?
 Yes 1.08 (0.58, 2.00) .
 No
Does the hospital have arrangements in place to receive pre‑hospital notification of stroke patients from the ambulance service?
 Yes 1.19 (0.69, 2.06) 1.02 (0.48, 2.18) 0.95
 No
Does the hospital have a dedicated Stroke Care Unit?
 Yes 1.02 (0.57, 1.84) 0.72 (0.25, 2.03) 0.53
 No
Does the hospital have an Intensive Care Unit?
 Yes 0.78 (0.28, 2.23) 2.46 (0.24, 24.87) 0.45
 No
Does the hospital have advanced imaging facilities (perfusion CT and MRI)?
 Yes 1.16 (0.57, 2.36) 2.28 (0.62, 8.38) 0.21
 No
The proportion of the emergency physicians at your hospital who routinely administer tPA treatment for eligible ischaemic stroke patients
 None 0.63 (0.35, 1.13) 0.96 (0.43, 2.11) 0.91
 Less than half/About half/Most/All
Does the head of emergency department routinely administer tPA treatment for eligible ischaemic stroke patients?
 Yes 4.05 (1.88, 8.72) 3.87 (1.49, 10.04) 0.01
 No/I don’t know
State
 NSW vs TAS 6.08 (0.77, 48.03)
 Vic vs TAS 4.09 (0.52, 32.46)
 QLD vs TAS 6.92 (0.87, 55.34)
 SA vs TAS 4.50 (0.45, 44.55)
 WA vs TAS 2.25 (0.22, 23.46)
 NT vs TAS 0.00 (0.00, I)
 ACT vs TAS 10.80 (0.91, 127.75)
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a desired behaviour [25]. Local opinion leaders in hospi-
tal settings can also be effective in promoting evidence-
based practice [23].
Limitations
The study yielded a low response rate (13%), limiting the 
generalizability of the sample and power of the study. It is 
possible that only individuals with a strong opinion about 
tPA use responded. However, low response rates among 
health-care providers is common and our results are not 
dissimilar to other online surveys of physicians [26–29]. 
Hospital characteristics were obtained via self-report 
and therefore may not be accurate. Hospital location was 
not obtained, therefore it is not clear how representa-
tive results are of physicians working in urban vs rural 
hospitals.
The survey did not measure respondents’ knowledge 
of guidelines or criteria for tPA use in stroke, or whether 
individual physicians had previously administered or 
were likely to administer tPA. These items may have been 
associated with high agreement with evidence supporting 
tPA use as previous use of tPA for stroke is independently 
associated with a willingness to use tPA [10]. Future stud-
ies should measure these constructs. While it is acknowl-
edged that there is conflicting evidence on the use of tPA 
for acute stroke, the study was specifically designed to 
assess perceptions on the use of, and evidence support-
ing, tPA. The terms ‘appropriate’ and ‘treatment pro-
tocol’ were used in a number of survey items, assuming 
a shared meaning of being in accordance with clinical 
practice guidelines [5]. In addition, as administration of 
tPA within 6 h of stroke onset significantly increases the 
odds of being alive and independent at follow-up [4], the 
term ‘save lives’ was intended to refer to an improvement 
in quality of life and DALYs, rather than a reduction in 
mortality. However, as these terms, along with the word 
‘unnecessary’, were not defined within the survey, inter-
pretation may differ among respondents.
Finally, 345 NZ fellows and trainees within ACEM were 
accidently sent the invitation email by ACEM. Although 
the total number of NZ members has not been included 
in the denominator, results may contain a number of NZ 
responders (estimated maximum of 1.4% of responders). 
The invitation to NZ members was rescinded immedi-
ately and is unlikely to have influenced results.
Conclusions
This was the first study to examine rates of agreement 
with evidence supporting tPA use in acute stroke care, as 
well as the individual and hospital factors associated with 
agreement with the evidence among Australian emer-
gency physicians. Our results correspond with previous 
international literature, finding low rates of agreement 
with particular published literature on the potential ben-
efits of tPA use among responding emergency physicians.
Study results demonstrate that attitudes among emer-
gency health-care providers may in fact be one of the 
factors limiting tPA administration rates. Agreement 
with clinical practice guidelines for stroke is likely to be 
necessary if tPA treatment is to become widely adopted 
in hospitals possessing the appropriate facilities. Future 
research should explore strategies to increase participation 
in research among specialist physicians to overcome low 
response rates and increase the generalisability of study 
findings. In addition, examination of the effectiveness of 
health-provider targeted interventions with a focus on 
social influence and modelling to increase physician agree-
ment with clinical practice guidelines is an area in need 
of further research. Our findings that the opinions and 
actions of ED heads and professional colleagues influence 
emergency physicians’ views may be valuable informa-
tion to clinical leaders and shape their practice in ensuring 
health-care provider adherence to clinical guidelines.
Emergency physicians’ perceptions represent a poten-
tially modifiable barrier to the use of tPA treatment. An 
increase in emergency physician agreement with the 
literature regarding tPA use in acute stroke may have 
the potential to produce substantial benefits for stroke 
patients.
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